News

05-2022 Megadalton presents new work at the ASGCT Annual Meeting

Work from Megadalton Solutions, Indiana University and Pfizer covering the CDMS analysis of DNA released from AAV Vectors.

05-2022 Megadalton presents on CDMS analysis of AAV vectors at the PEGS Conference

We were delighted to present work on our characterization of AAV vectors by CDMS.

02-2022 Waters licenses CDMS IP from Megadalton

Waters and Megadalton reach an agreement to co-develop CDMS technology. While allowing Megadalton to continue offering CDMS research collaborations.

08-2021 Megadalton Solutions and Waters commission a CDMS instrument in Cambridge

Megadalton Solutions delivered a new CDMS instrument the Waters Immerse Center in Cambridge, MA. The instrument offers high throughput and high resolution analysis of a wide range of biomolecules.

11-2020 Megadalton Solutions and Waters Team up

Megadalton Solutions and Waters team up to bring CDMS to Cell and Gene Therapy sectors at Waters Immerse Center.

10-2020 Megadalton Presents at ASGCT COVID Symposium

Megadalton Solutions presented recent SARS-COV-2 related research including analysis of Intact Spike Protein Trimers, AAV, and Adenovirus. Contact for copy of poster.

03-2020 Megadalton Solutions begins SARS-COV-2 Research

Megadalton Solutions continues essential research during the COVID-19 lockdown applying CDMS measurements to beta-coronaviruses, the spike protein, and vaccine delivery platforms.

03-2020 Megadalton Solutions Awarded Phase 2 SBIR Grant

Megadalton Solutions has been awarded a Phase 2 SBIR grant to build-out measurement capacity to address the growing demand of gene therapy analysis.

02-2020 Megadalton Solutions presents at the USP Gene Therapy Workshop

Megadalton Solutions presented how CDMS could be used for the analysis of AAV.

04-2019 Megadalton Solutions Awarded Phase 1 SBIR Grant

Megadalton has been awarded a Phase 1 proposal to fast-track commercialization of a commercial CDMS platform.